On March 11, 2021 Incyte (Nasdaq:INCY) reported that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, held virtually from April 10-15, 2021 (Press release, Incyte, MAR 11, 2021, View Source [SID1234576453]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At AACR (Free AACR Whitepaper) 2021, we look forward to sharing clinical and pre-clinical data from INCB106385, our novel A2A/A2B adenosine receptor antagonist, and INCA00186, our novel CD73 monoclonal antibody—both of which highlight our ongoing efforts targeting the adenosine pathway. Presentations at the congress will also feature updated data from our LIMBER development program, including results from our Phase 2 combination study of ruxolitinib, a janus kinase (JAK1/JAK2) inhibitor, and parsaclisib, a potent, highly selective oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ)," said Steven Stein, M.D., Chief Medical Officer, Incyte, adding, "We further look forward to sharing clinical and pre-clinical data on these and other targeted and immuno-oncology therapies in the Incyte portfolio."
Key abstracts from Incyte-sponsored and partner programs include:
Targeted Therapy
Addition of Parsaclisib (INCB050465), a PI3Kδ Inhibitor, in Patients with Suboptimal Response to Ruxolitinib: A Phase 2 Study in Patients with Myelofibrosis (Abstract #CT162, Session: Phase II Clinical Trials.)
The LSD1 Inhibitor INCB059872 is a Possible Therapeutic Option for Venetoclax-Resistant AML (Abstract #1134, Session: Epigenetic Targets.)
Accurate Detection of MET Exon 14 Skipping Using Liquid Biopsy Assay in NSCLC Patients in the GEOMETRY Mono-1 Study 1 (Abstract # LB056, Session: Liquid Biopsies: Circulating DNA.)
Immuno-Oncology
Discovery and Preclinical Characterization of INCB106385, a Novel A2A/A2B Adenosine Receptor Antagonist, as a Cancer Immunotherapy (Abstract #LB157, Session: Immune Checkpoints.)
Discovery and Preclinical Characterization of INCA00186, a Humanized Monoclonal Antibody Antagonist of CD73, as a Cancer Immunotherapy (Abstract #LB174, Session: Therapeutic Antibodies, Including Engineered Antibodies.)
All presentation sessions will be available on demand beginning April 10, 2021 at 8:30 a.m. ET, through June 21, 2021. Full session details and listings for oral and e-poster presentations are available online via the AACR (Free AACR Whitepaper) 2021 program: View Source!/9325.